Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Purchases $314,000.00 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director John Patience purchased 200,000 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the purchase, the director now owns 653,224 shares in the company, valued at $1,025,561.68. The trade was a 44.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Accelerate Diagnostics Stock Down 4.8 %

Accelerate Diagnostics stock traded down $0.08 during trading hours on Tuesday, reaching $1.57. 32,036 shares of the company were exchanged, compared to its average volume of 45,497. Accelerate Diagnostics, Inc. has a 12 month low of $0.73 and a 12 month high of $5.23. The stock has a 50-day moving average of $1.81 and a 200 day moving average of $1.53.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 17.14% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Accelerate Diagnostics in a research report on Tuesday. They issued a “hold” rating on the stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.